Open AccessAssociation of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes
Author(s) -
Amar U. Kishan,
Xiaoyan Wang,
Wendy Seiferheld,
Laurence Collette,
Kiri A. Sandler,
Howard M. Sandler,
M. Bolla,
P. Maingon,
Theo de Reijke,
Gerald E. Hanks,
Nicholas G. Nickols,
Matthew B. Rettig,
Alexandra Drakaki,
Robert E. Reiter,
Daniel E. Spratt,
Patrick A. Kupelian,
Michael L. Steinberg,
Christopher King
Publication year - 2018
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2018.3732
Subject(s) - medicine , androgen deprivation therapy , prostate cancer , hazard ratio , proportional hazards model , oncology , radiation therapy , survival analysis , randomized controlled trial , cancer , confidence interval
Androgen deprivation therapy (ADT) improves survival outcomes in patients with high-risk prostate cancer (PCa) treated with radiotherapy (RT). Whether this benefit differs between patients with Gleason grade group (GG) 4 (formerly Gleason score 8) and GG 5 (formerly Gleason score 9-10) disease remains unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom